File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

TitleCan a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?
Authors
KeywordsPreoperative bevacizumab injection
Proliferative diabetic retinopathy
Vitreous haemorrhage
Issue Date2009
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eye
Citation
Eye, 2009, v. 23 n. 8, p. 1698-1701 How to Cite?
AbstractAims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3% at 1 week follow-up and 3, 6, and 6% respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91%). In all, 12 out of 22 (54%) phakic eyes developed cataract during the follow-up period, and 10 (31%) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH. © 2009 Macmillan Publishers Limited All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/60906
ISSN
2015 Impact Factor: 2.213
2015 SCImago Journal Rankings: 1.132
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRomano, MRen_HK
dc.contributor.authorGibran, SKen_HK
dc.contributor.authorMarticorena, Jen_HK
dc.contributor.authorWong, Den_HK
dc.contributor.authorHeimann, Hen_HK
dc.date.accessioned2010-05-31T04:21:33Z-
dc.date.available2010-05-31T04:21:33Z-
dc.date.issued2009en_HK
dc.identifier.citationEye, 2009, v. 23 n. 8, p. 1698-1701en_HK
dc.identifier.issn0950-222Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/60906-
dc.description.abstractAims: To evaluate the recurrence rate of vitreous haemorrhage (VH) in patients treated with one intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 ml) before planned pars plana vitrectomy for treatment of diabetic non-clearing VH. Methods: Prospective pilot study of 32 eyes of 31 consecutive diabetic patients who underwent IVB injection within 1 week before surgery for persistent VH in the presence of active proliferative diabetic retinopathy. Three masked retinal specialists graded the amount of VH from grade 0 to grade 3 with slit-lamp biomicroscopy. Main outcome measures were the rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results: The percentage of severe recurrent VH with no fundus details (grade 3) was 3% at 1 week follow-up and 3, 6, and 6% respectively at 1-, 3-, and 6-month follow-up. The mean best-corrected visual acuity (BCVA) improved from 1.6 (1/60) to 0.40 (6/15) logMAR (P=0.02) in 29 out of 32 eyes (91%). In all, 12 out of 22 (54%) phakic eyes developed cataract during the follow-up period, and 10 (31%) of them underwent cataract surgery. Conclusions: Our study suggests that IVB injection few days before planned surgery seems to be efficacious and safe as an adjuvant treatment to prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous haemorrhage. IVB facilitates the surgery and reduces the need for extensive delamination and segmentation, decreasing the possibility of significant early active postoperative VH. © 2009 Macmillan Publishers Limited All rights reserved.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/eyeen_HK
dc.relation.ispartofEyeen_HK
dc.subjectPreoperative bevacizumab injectionen_HK
dc.subjectProliferative diabetic retinopathyen_HK
dc.subjectVitreous haemorrhageen_HK
dc.subject.meshAngiogenesis Inhibitors - administration and dosage-
dc.subject.meshAntibodies, Monoclonal - administration and dosage-
dc.subject.meshDiabetic Retinopathy - etiology - surgery-
dc.subject.meshVitrectomy-
dc.subject.meshVitreous Hemorrhage - prevention and control-
dc.titleCan a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0950-222X&volume=23&issue=8&spage=1698&epage=1701&date=2008&atitle=Can+a+preoperative+bevacizumab+injection+prevent+recurrent+postvitrectomy+diabetic+vitreous+haemorrhage?-
dc.identifier.emailWong, D: shdwong@hku.hken_HK
dc.identifier.authorityWong, D=rp00516en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/eye.2008.354en_HK
dc.identifier.pmid19039332-
dc.identifier.scopuseid_2-s2.0-69049096319en_HK
dc.identifier.hkuros154791en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-69049096319&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1698en_HK
dc.identifier.epage1701en_HK
dc.identifier.isiWOS:000268915900013-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridRomano, MR=35249070500en_HK
dc.identifier.scopusauthoridGibran, SK=13205333800en_HK
dc.identifier.scopusauthoridMarticorena, J=14043688500en_HK
dc.identifier.scopusauthoridWong, D=7401536078en_HK
dc.identifier.scopusauthoridHeimann, H=7006780277en_HK
dc.identifier.citeulike3726659-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats